Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Michael J. Keating et al.|New England Journal of Medicine|2019Cited by 502
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Catherine J. Wu, Vivian M. Liu et al.|Cancer Cell|2019Cited by 361
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Caitlin R. Rausch et al.|The Lancet Haematology|2020Cited by 330
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimensPhilip A. Thompson, Michael J. Keating|Cancer|2015Cited by 247
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S. Davids, Jennifer R. Brown, Kerry A. Rogers et al.|Blood|2021Cited by 75